Four things you should know about the pending Charter challenge against Medicare

By Colleen Flood and Kathleen O’Grady, EvidenceNetwork.ca A version of this commentary appeared in the Globe and Mail, the Medical Post and the Windsor Star A long-running dispute between Dr. Brian Day, the co-owner of Cambie Surgeries Corporation and the British Columbia government may finally be resolved in the BC Supreme Court next year — and the ruling could transform the Canadian health system from coast to coast. The case emerged

Take part in CCSN’s important survey on Xgeva!

The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of denosumab (Xgeva) for the prevention of skeletal-related events due to bone metastases from solid tumours. The information gathered from this survey will be used in order to prepare a patient evidence submission to the CADTH Common Drug Review. Please note that your personal

Finding Flexible Work Difficult for Cancer Patients and Caregivers

New data released on financial, decision-making and emotional burden of cancer LAVAL, Quebec, January 14, 2014 – A 2013 Léger national survey of cancer patients and their caregivers, commissioned by Sanofi Canada, sheds new light on the striking financial, decision-making and emotional burden the disease puts on cancer patients and their caregivers.  The survey finds that 18% of patients experience difficulty in finding flexible work options

Survey Highlights Ontarians’ Perceptions on Access to Medications in Canada

Only one-fifth believe that if they were diagnosed with cancer today, all their medications would be covered by their province’s healthcare system or medical insurance1 TORONTO, June 14, 2012 /CNW/ – Ontarians know what they want from their healthcare system when it comes to medication.  According to the results of a recent survey, the vast majority of Ontarians (76 per cent) strongly feel that if

ZYTIGA® Now Available for Eligible Patients in Nova Scotia and Newfoundland and Labrador

Provinces are fifth and sixth in Canada to reimburse new metastatic prostate cancer treatment Toronto, ON (May 16, 2012) – Men living with metastatic prostate cancer in Nova Scotia and Newfoundland and Labrador now have access to a new treatment option, as these provinces have made the decision to include ZYTIGA® (abiraterone acetate) on their public formularies for the treatment of metastatic, castration-resistant prostate cancer.